INTRODUCTION: Patients with incidental pT2-T3 gallbladder cancer (IGC) after a cholecystectomy may benefit from a radical re-resection although their optimal treatment strategy is not well defined. In this Unit, such patients undergo delayed staging at 3 months after a cholecystectomy to assess the evidence of a residual tumour, extra hepatic spread and the biological behaviour of the tumour. The aim of this study was to evaluate the outcome of patients who had delayed staging at 3 months after a cholecystectomy. METHODS: From July 2003 to July 2011, 56 patients with T2-T3 gallbladder cancer were referred to this Unit of which 49 were diagnosed incidentally on histology after a cholecystectomy. All 49 patients underwent delayed pre-operative staging using multi-detector computed tomography (MDCT) followed selectively by laparoscopy at 3 months after a cholecystectomy. Data were collected from a prospectively held database. The peri-operative and long-term outcomes of patients were analysed. SPSS software was used for statistical analysis. RESULTS: There were 38 pT2 and 11 pT3 tumours. After delayed staging, 24/49 (49%) patients underwent a radical resection, 24/49 (49%) were found to be inoperable on pre-operative assessment and 1/49 (2%) patient underwent an exploratory laparotomy and were found to be unresectable. The overall median survival from referral was 20.7 months (54.8 months for the group who had a radical re-resection versus 9.7 months for the group who had unresectable disease, P < 0.001). These results compare favourably with the reported outcome of fast-track management for incidental pT2-T3 gallbladder cancer from other major series in the literature. CONCLUSION: Delayed staging in patients with incidental T2-T3 gallbladder cancer after a cholecystectomy is a useful strategy to select patients who will benefit from a resection and avoid unnecessary major surgery.
INTRODUCTION:Patients with incidental pT2-T3 gallbladder cancer (IGC) after a cholecystectomy may benefit from a radical re-resection although their optimal treatment strategy is not well defined. In this Unit, such patients undergo delayed staging at 3 months after a cholecystectomy to assess the evidence of a residual tumour, extra hepatic spread and the biological behaviour of the tumour. The aim of this study was to evaluate the outcome of patients who had delayed staging at 3 months after a cholecystectomy. METHODS: From July 2003 to July 2011, 56 patients with T2-T3 gallbladder cancer were referred to this Unit of which 49 were diagnosed incidentally on histology after a cholecystectomy. All 49 patients underwent delayed pre-operative staging using multi-detector computed tomography (MDCT) followed selectively by laparoscopy at 3 months after a cholecystectomy. Data were collected from a prospectively held database. The peri-operative and long-term outcomes of patients were analysed. SPSS software was used for statistical analysis. RESULTS: There were 38 pT2 and 11 pT3 tumours. After delayed staging, 24/49 (49%) patients underwent a radical resection, 24/49 (49%) were found to be inoperable on pre-operative assessment and 1/49 (2%) patient underwent an exploratory laparotomy and were found to be unresectable. The overall median survival from referral was 20.7 months (54.8 months for the group who had a radical re-resection versus 9.7 months for the group who had unresectable disease, P < 0.001). These results compare favourably with the reported outcome of fast-track management for incidental pT2-T3 gallbladder cancer from other major series in the literature. CONCLUSION: Delayed staging in patients with incidental T2-T3 gallbladder cancer after a cholecystectomy is a useful strategy to select patients who will benefit from a resection and avoid unnecessary major surgery.
Authors: Philippe Marc Glauser; Daniel Strub; Samuel Andreas Käser; Diana Mattiello; Franziska Rieben; Christoph Andreas Maurer Journal: Surg Endosc Date: 2010-02-23 Impact factor: 4.584
Authors: Ajay V Maker; Jean M Butte; Jacqueline Oxenberg; Deborah Kuk; Mithat Gonen; Yuman Fong; Ronald P Dematteo; Michael I D'Angelica; Peter J Allen; William R Jarnagin Journal: Ann Surg Oncol Date: 2011-06-23 Impact factor: 5.344
Authors: David Fuks; Jean Marc Regimbeau; Yves-Patrice Le Treut; Philippe Bachellier; Artivas Raventos; François-René Pruvot; Laurence Chiche; Olivier Farges Journal: World J Surg Date: 2011-08 Impact factor: 3.352
Authors: Samuel P Shih; Richard D Schulick; John L Cameron; Keith D Lillemoe; Henry A Pitt; Michael A Choti; Kurtis A Campbell; Charles J Yeo; Mark A Talamini Journal: Ann Surg Date: 2007-06 Impact factor: 12.969
Authors: T Tsirlis; F Ausania; S A White; J J French; B C Jaques; R M Charnley; D M Manas Journal: Ann R Coll Surg Engl Date: 2015-03 Impact factor: 1.891
Authors: John M Creasy; Debra A Goldman; Vikas Dudeja; Maeve A Lowery; Andrea Cercek; Vinod P Balachandran; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Michael I D'Angelica; William R Jarnagin Journal: J Am Coll Surg Date: 2017-02-13 Impact factor: 6.113
Authors: John M Creasy; Debra A Goldman; Mithat Gonen; Vikas Dudeja; Eileen M O'Reilly; Ghassan K Abou-Alfa; Andrea Cercek; James J Harding; Vinod P Balachandran; Jeffrey A Drebin; Peter J Allen; T P Kingham; Michael I D'Angelica; William R Jarnagin Journal: HPB (Oxford) Date: 2019-04-23 Impact factor: 3.647
Authors: John M Creasy; Debra A Goldman; Mithat Gonen; Vikas Dudeja; Gokce Askan; Olca Basturk; Vinod P Balachandran; Peter J Allen; Ronald P DeMatteo; Michael I D'Angelica; William R Jarnagin; T Peter Kingham Journal: J Gastrointest Surg Date: 2017-05-08 Impact factor: 3.452
Authors: Elise de Savornin Lohman; Tessa de Bitter; Rob Verhoeven; Lydia van der Geest; Jeroen Hagendoorn; Nadia Haj Mohammad; Freek Daams; Heinz-Josef Klümpen; Thomas van Gulik; Joris Erdmann; Marieke de Boer; Frederik Hoogwater; Bas Groot Koerkamp; Andries Braat; Joanne Verheij; Iris Nagtegaal; Cornelis van Laarhoven; Peter van den Boezem; Rachel van der Post; Philip de Reuver Journal: Cancers (Basel) Date: 2020-04-09 Impact factor: 6.639